Clinical trial · Interventional
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
NCT01765231CI-TRIAL-00025432unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis B | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Entecavir prophylaxis | Drug | — | UNRESOLVED |
| Observation arm | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Entecavir prophylaxis
- description
- Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
- interventionNames
- Drug: Entecavir prophylaxis
- type
- ACTIVE_COMPARATOR
- label
- Observation arm
- description
- Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
- interventionNames
- Drug: Observation arm
Primary outcomes (1)
- measure
- the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * treatment-naive patients with lymphoma * HBsAg negative/HBcAb positive/hepatitis B virus DNA negative at baseline * treated with chemotherapy and/or immunosuppressive therapy * life expectancy of more than 3 months Exclusion Criteria: * younger than 18 years old * HBsAg positive or HBcAb negative or hepatitis B virus DNA positive at baseline * pregnant or lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.